Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain

Leukemia Research

Volumn 36, Issue 6, 2012, Pages 709-714

  Sanchez Gonzalez, Blanca ^a   Peñalver, F Javier ^b   Medina, Angeles ^c   Guillén, Helga ^d   Calleja, Marta ^d   Gironella, Mercedes ^e   Arranz, Reyes ^f   Sebastian, Elena ^g   de Oña, Raquel ^h   Cánovas, Araceli ⁱ   de la Fuente, Ignacio ^g   Grande, Carlos ^j   Sancho, Juan Manuel ^k   Perez, Ricardo ^l   Domingo, Eva ^m   Lopez Lorenzo, José Luis ⁿ   Prieto, Elena ⁿ   Panizo, Carlos ^o   Gorosquieta, Ana ^p   Perez, Inmaculada ^q   Cervera, Jose Manuel ^r   Marin, Miguel ^s   Mencha, Carmen ^t   Ramila, Elena ^u   Salar, Antonio ^u   more..

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^c Hospital de la Costa del Sol   (Spain)

^d HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^g HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^h MD ANDERSON CANCER CENTER   (Spain)

ⁱ HOSPITAL DE CRUCES   (Spain)

^j HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^k HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^l HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^m CATALAN INSTITUTE OF ONCOLOGY   (Spain)

ⁿ Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^o UNIVERSITY CLINIC OF NAVARRA   (Spain)

^p Instituto de Investigación Sanitaria de Navarra   (Spain)

^q HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^r Hospital Clínica Benidorm   (Spain)

^s Department of Hematology   (Spain)

^t HOSPITAL TXAGORRITXU   (Spain)

^u Hospital Parc Tauli   (Spain)

more..

Author keywords

Antineoplastic agents; Bendamustine; Chronic lymphocytic leukemia; Non Hodgkin lymphoma; Prognosis; Rituximab

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BENDAMUSTINE; DEXAMETHASONE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; BACTEREMIA; BLOOD TOXICITY; CANCER RESISTANCE; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; ENTEROPATHY ASSOCIATED T CELL LYMPHOMA; FEMALE; FOLLICULAR LYMPHOMA; HEPATITIS B; HEPATITIS C; HERPES ZOSTER; HISTOPATHOLOGY; HUMAN; LARGE CELL LYMPHOMA; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SECOND CANCER; SPAIN; STEM CELL TRANSPLANTATION; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NITROGEN MUSTARD COMPOUNDS; RETROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME;

EID: 84859853309     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.10.024     Document Type: Article

References (21)

1. Salar A., Fernández de Sevilla A., Romagosa V., et al. Distribution and incidence rates of lymphoid neoplasms according to the REAL classification in a single institution. A prospective study of 940 cases. Eur J Haematol 1997, 59:231-237.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002, updated as of October 27. CA Cancer J Clin 2009, 55:74-108.
3. Horning S.J Natural history of and therapy for the indolent non-Hodgkin'slymphomas. Semin Oncol 1993, 20:75-88.
4. Hiddemann W., Kneba M., Dreling M., et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade lymphoma Study Group. Blood 2005, 106:3725-3732.
5. Leoni L.M., Bailey B., Reifert J., et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008, 14:309-317.
6. Friedberg J.W., Cohen P., Chen L., et al. Bendamustine in patients with rituximab-refractory and alkylator-refractory, indolent, and transformed non-Hodgkin's lymphoma: results from a phase II multicenter single-agent study. J Clin Oncol 2008, 26:204-210.
7. Heider A., Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs 2001, 12:725-729.
8. Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin'slymphomas. J Cancer Res Clin Oncol 2002, 128:603-609.
9. Kath R., Blumenstengel K., Fricke H.J., et al. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 2001, 127:48-54.
10. Weidmann E., Kim S.Z., Rost A., et al. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2002, 13:1285-1289.
11. Bergmann M.A., Goebeler M.E., Herold M., et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL study group. Haematologica 2005, 90:1357-1364.
12. Robinson K.S., Williams M.E., van der Jagt R.H., et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent b-cell and manle cell non-Hodgkin's lymphomas. J Clin Oncol 2008, 26:4473-4479.
13. Fischer K., Stilgenbauer S., Schweighofer C.D., et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL study group (GCLLSG). J Clin Oncol 2011, 29:3559-3566.
14. Koppler H., Heymanns J., Pandorf A., Weide R. Bendamustine plus mitoxantrone-a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study. Leuk Lymphoma 2004, 45:911-913.
15. Weide R., Pandorf A., Heymanns J., Koppler H. Bendamustine/mitoxantrone/rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma 2004, 45:2445-2449.
16. Rummel M.J., von Gruenhagen U., Niederle N., et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle-cell lymphomas: the first interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2007, 110:120a. [abstr 385].
17. Sanchez-Gonzalez B., Garcia M., Serrano S., Besses C., Salar A. Bendamustine-containing immunochemotherapy is active in transformed follicular lymphoma with overexpression of p53. Leuk Lymphoma 2009, 50:455-456.
18. Cheson B.D., Pfistner B., Juweid M.E., et al. International harmonization project on lymphoma revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
19. Hallek M., Cheson B.D., Catovsky D., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leucemia: a report from the International Workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446-5456.
20. National Cancer Institute: Common Terminology Criteria for Adverse Events v3.0. 2003. http://ctep.cancer.gov/reporting/ctc.html.
21. Iannitto E., Morabito F., Mancuso S., et al. Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study. Br J Haematol 2011, 153:351-357.